Abstract.
Targeted therapies have often given disappointing results when used as single agents in solid tumors, suggesting the importance of devising rational combinations of targeted drugs. We hypothesized that construction of such combinations could be guided by identification of growth and survival pathways whose activity or expression become upregulated in response to singleagent drug treatment. We mapped alterations in signaling pathways assessed by gene array and protein phosphorylation to identify compensatory signal transduction pathways in prostate cancer xenografts treated with a MEK inhibitor, PD325901. In addition to numerous components of the ERK signaling pathway, components of the IKK, Hedgehog, and PI3 Kinase/Akt/mTOR pathways were up regulated following treatment with PD325901. Combinations of PD325901 with inhibitors of any one of these upregulated pathways provided synergistically greater growth inhibition of in vitro cell growth and survival than the individual drugs alone. Thus, the identification of compensatory signal transduction pathways paves the way for rational combinatorial therapies for the effective treatment of prostate cancer.
Introduction.
Inhibitors targeting signaling molecules that are overexpressed and activated in cancer have shown only modest clinical benefit when used as single agents (1, 2) . One explanation for this may rest in recent data demonstrating that extracellular signals are transmitted through a network of proteins rather than through hierarchical signaling pathways (3) (4) (5) . This network model explains why inhibition of a single component of a canonical pathway is usually insufficient to have dramatic effects on the treatment of cancer: the biological outcome of signals propagated through a network is inherently more robust and resistant to inhibition of a single network component (6) . Thus, it is becoming increasingly clear that for many cancers the most effective use of molecular targeted therapies for cancer will require a combination of several agents that inhibit key nodes or fragile points in the network.
However, the difficulty of developing combinations of targeted agents is geometrically more difficult than developing a single agent. Ideally, one would be able to identify pathways that compensate for or blunt the cytotoxic effects of single agents, and then utilize a second agent that targets this compensatory pathway. One potentially effective paradigm for identifying these pro-growth and survival compensatory signaling events is to identify changes in activity or expression of signaling components that are induced by specific targeted therapeutics. Here we demonstrate that these induced signaling changes do, in fact, reveal functionally significant compensatory changes and hence therapeutic targets that can guide the construction of rational therapies.
In prostate cancer, prior work by us and others suggests that activation of Ras signaling plays an important role in progression of prostate cancer to advanced, castration resistant disease (7) (8) (9) . In earlier work we showed that activation of MAP kinase, an effector of Ras activation, correlates with prostate cancer progression in patient samples (9) . Moreover, activation of Ras signaling was sufficient to reduce androgen dependence of growth in cultured cells and xenografts (8) . Additionally, Ras-related signaling was necessary for castration resistant growth, as inhibition of Ras activity with dominant negative Ras restored androgen dependence both in vitro and in vivo (7) . Taken together these results suggest that inhibition of Ras and/or its effectors such as MEK could be an effective therapy for advanced prostate cancer.
In this study we show, contrary to expectations, that inhibition of MEK was only partially effective at blocking castration-resistant growth of prostate cancer xenografts, suggesting that other pathways besides the MAP kinase pathway need to be co-targeted to achieve full therapeutic benefit in vivo. We identified several pro-growth and survival compensatory signaling pathways whose activity or expression were induced by inhibiting MEK in prostate cancer xenografts. We found that combining inhibitors of these compensatory responses with MEK inhibition effectively blocked cell growth. antibody from EMD Biosciences. Western blots were performed as previously described (10 (Applied Biosystems, Bedford, MA), 0.5% Tween-20 in 500mL PBS) with constant rocking at 4°C. Staining used an automated slide stainer (DAKO, Carpinteria, CA) using a biontinyl-linked peroxidase catalyzed signal amplification system as per the manufacturer's recommendation and components from the manufacturer's kit, unless otherwise indicated as previously described (15). Slides were stained with a set of 39 antibodies against phosphorylated or total forms of proteins involved in cell proliferation, survival, motility and apoptosis signaling. A complete list of antibodies, sources and dilutions used for these experiments is available in Supplementary Table 1 . Stained slides were scanned individually on a UMAX PowerLook III scanner (UMAX, Dallas, TX) at 600 dpi and saved as TIF files in Photoshop 7.0 (Adobe, San Jose, CA). The TIF images for antibody-stained slides and Sypro-stained slide images were analyzed using MicroVigene v2.8.1.0 (VigeneTech, Carlisle, MA). Briefly, final data values for each sample were calculated using the factor average mode, and all values were negative control subtracted and normalized to total protein. 
PD325901 is highly selective in vivo.
In order to assess the selectivity of PD325901 in vivo, castrated and sham operated nude mice carrying CWR22Rv1 tumors were treated with a single 25mg/kg dose of PD325901. Tumors were harvested at 2, 6, and 14 hours posttreatment. Western blot analysis showed effective inhibition of ERK phosphorylation at all times, although phospho-ERK levels were inhibited to a greater extent at 2 and 6 hours when compared to 14 hours post PD325901 treatment (Figure 2A) . Analyzing xenografts over time by reverse phase protein array (RPMA) following a single dose of PD325901 showed a rapid decrease in only ERK phosphorylation ( Figure 2B) . Again, phospho-ERK levels are maximally suppressed at 2 and 6 hours. By 14 hours post PD325901 treatment phospho-ERK levels are still below control but have begun to rise. Thirty-eight different phosphorylation sites in tumor lysates were examined by RPMA (Supplemental Table 1 ). Only ERK and p90RSK, a kinase 
of xenografts were analyzed: control vehicle treated animals, PD325901 treated animals, and animals treated with PD325901 for three weeks and then allowed to recover for two weeks.
Tumors were excised and divided, with representative tumor pieces from comparably sized tumors processed for protein or RNA analysis.
For gene array studies, RNA was isolated and analyzed using Affymetrix HgU133_Plus 2 gene chips. The treated and untreated samples clustered separately as expected. 5294 genes were scored as "upregulated" at least 1.5 fold P<0.05, and 833 genes were "downregulated" following treatment with PD325901. We found that approximately half the genes whose expression changed following treatment remained at least partially upregulated or downregulated even after drug was withdrawn, suggesting that MEK inhibition in prostate tumors led to persistent changes in the transcriptome. We used the Pathway Express tool to identify pathways affected by the differentially expressed genes (13) . This revealed that numerous components of the ERK signaling pathway were upregulated in response to PD325901 treatment, including SOS, K-Ras, Rap1a, c-Raf, B-Raf, ERK1, ERK2, and MP1, as if massive overexpression of the pathway was a mechanism for overcoming the signaling blockade ( Figure 4A) . Furthermore, we found transcription of additional pathways were substantially upregulated following treatment with PD325901 ( Figure 4B ). Some were expected, such as PI3 Kinase and Akt. Others were more surprising, such as genes from the Sonic Hedgehog pathway, including Patched, DYRK1, and FU as well as genes of the Wnt, and Notch signaling pathways. It is striking that the pathways that change in response to MEK inhibition have been shown to be important in prostate development and/or cancer (21) (22) (23) (24) .
To determine the functional activation state of the signaling pathways, phosphorylation levels of key signaling proteins within these xenografts was analyzed using RPMA. ERK phosphorylation was inhibited for the three weeks of drug treatment and then returned to normal when drug was removed, as expected ( 
Discussion.
In our work, we have performed a functional protein signal pathway activation mapping and gene expression analysis of prostate tumor xenografts treated with a MEK inhibitor and found that MAP kinase inhibition caused hyperactivation of the upstream components of the canonical MAPK pathway as well as upregulation of other signaling events regulating cell growth and survival. This demonstrates the problem in basing a therapy on a simple catalogue of activated proteins in cancer cells, because an aberrantly activated protein could be part of a feedback or feed-forward control system. Without knowing its network role, inhibiting this protein could result in contributing to disease progression rather than curative therapy.
Previous studies have highlighted the complexity of selecting a targeted therapeutic agent based on the activation of a single network component (26, 27, 34) . Elevated mTOR activity has been observed in multiple cancers and mTOR inhibitors have shown robust activity in model systems. However, the clinical trial results with mTOR inhibitors have been more modest than predicted (27) . Studies have shown that while inhibiting mTOR activity in lung, breast, colon, and prostate cancer cells effectively suppressed the phosphorylation of downstream effectors such as p70S6K and 4EBP1, it increased the phosphorylation of AKT (26, 27) . This increase in AKT activity attenuated the effect of mTOR inhibition and facilitated cancer cell growth and survival. Only upon discovery of this mTOR -AKT feedback control system could effective combinatorial treatments be determined; inhibition of IGFR-1 in breast and prostate cancer cell lines, and of PI3K in lung cancer cell lines, sensitized cells to mTOR inhibition (26, 27) .
We utilized global analysis of protein activation and gene expression to identify compensatory events and facilitate the design of effective drug combinations. The usefulness of global analysis for identifying drug combinations was recently demonstrated using the KrasG12V/Lkb1-/-mouse model for NSCLC (35) . Analysis of gene expression and phosphoproteome profiles between primary KrasG12V tumors, primary KrasG12V/ Lkb1-/- When we combined inhibitors of IKK (NFκB pathway), or mTOR (Phosphatidyl inositol pathway) with MEK inhibition we observed synergistic cytotoxicity in CWR22Rv1 cells and we observed additivity when we combined MEK and Hedgehog inhibition according to Bliss Independence (17, 18) . Not yet determined is the precise mechanism of synergy with these drug combinations. An increase in NFκB signaling has been associated with prostate cancer (36) . Moreover, a recent study has found that inflammatory infiltration and activation of IKKalpha in tumor cells is associated with prostate cancer progression (28) Hedgehog signaling is a major regulator of cellular differentiation and proliferation that is elevated in prostate cancer (29) . Previous studies have suggested cross talk between Hedgehog and MAPK signaling; specifically ERK involvement in Gli regulation (41) (42) (43) . In 
